{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T17:59:13Z","timestamp":1649095153023},"reference-count":10,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1503,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1111\/j.1756-185x.2011.01637.x","type":"journal-article","created":{"date-parts":[[2011,7,21]],"date-time":"2011-07-21T10:20:52Z","timestamp":1311243652000},"page":"340-344","source":"Crossref","is-referenced-by-count":4,"title":["Leflunomide in clinical practice. A retrospective observational study on use of leflunomide in New Zealand"],"prefix":"10.1111","volume":"14","author":[{"given":"Jayathri Sandalekha","family":"JAGODA","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chula Niranjan Ajasath","family":"RAJAPAKSE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,7,21]]},"reference":[{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.59.11.841","article-title":"Leflunomide: mode of action in the treatment of rheumatoid arthritis","volume":"59","author":"Breedveld","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2125.2004.02075.x","article-title":"Leflunomide in active Rheumatoid arthritis: a prospective study in daily practice","volume":"57","author":"Von Roon","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB3|cit3","volume-title":"An Introduction to Medical Statistics","author":"Bland","year":"1996"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/ard.54.11.881","article-title":"Survival analysis of disease modifying antirheumatic drugs in Spanish rheumatoid arthritis patients","volume":"54","author":"De La Mata","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1136\/ard.62.10.944","article-title":"Survival and effectiveness of leflunomide compared with methotrexate and sulphasalazine in rheumatoid arthritis: a matched observational study","volume":"62","author":"Aletaha","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoeksra","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB7|cit7","article-title":"Audit of leflunomide in resistant Rheumatoid arthritis - 30 Month Follow-up. RA treatment: conventional DMARDS (Abstract No 253)","volume":"42","author":"Currey","year":"2003","journal-title":"Rheumatology"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB8|cit8","article-title":"Safety of leflunomide in rheumatoid arthritis; From clinical trials to clinical practice. RA treatment: conventional DMARDS. (Abstract No 252)","volume":"42","author":"Al Hassan","year":"2003","journal-title":"Rheumatology"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1136\/ard.54.9.708","article-title":"Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients","volume":"54","author":"Alarcon","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1111\/j.1756-185X.2011.01637.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1445-5994.2008.01792.x","article-title":"Leflunomide use in New Zealand. A national prospective post-marketing study","volume":"39","author":"White","year":"2009","journal-title":"Int Med J"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2011.01637.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1756-185X.2011.01637.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,4]],"date-time":"2021-02-04T22:49:25Z","timestamp":1612478965000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1111\/j.1756-185X.2011.01637.x"}},"subtitle":["Leflunomide in clinical practice"],"short-title":[],"issued":{"date-parts":[[2011,7,21]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,10]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2011.01637.x","relation":{},"ISSN":["1756-1841"],"issn-type":[{"value":"1756-1841","type":"print"}],"subject":[],"published":{"date-parts":[[2011,7,21]]}}}